SYN-002 / Synergys Biotherap - LARVOL DELTA

RESPECT-CMV: Renal Ex Vivo SYN002 Perfusion to Eliminate CMV Transmission (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: University Health Network, Toronto

New P1 trial • Cytomegalovirus Infection • Infectious Disease • Transplantation

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin. (PubMed, Am J Transplant) - "SYN002 treatment during NMP appeared safe and reduced HCMV levels in cells isolated from kidney perfusates. The study provides compelling proof-of-concept that SYN002 is efficacious and safe and that the use of SYN002 in this setting can be expected to provide clinical benefit."

Journal • Preclinical • Cytomegalovirus Infection • Infectious Disease • Solid Organ Transplantation • Transplantation

Ex Vivo Targeting of the Latent Cytomegalovirus Reservoir in Human Kidneys to Prevent Virus Reactivation Post Transplantation (WTC 2025) - "Treatment for CMV during NMP appeared safe and reduced the foci of infection in cells isolated from the perfusate. The ex vivo data provide compelling proof-of-concept that SYN002 is highly efficacious and safe and that the use of SYN002 in this setting can be expected to provide clinical benefit. SYN002 constitutes a novel approach for the prevention of transplantation associated CMV reactivation and disease without the need for antiviral prophylaxis."

Late-breaking abstract • Post-transplantation • Preclinical • Cytomegalovirus Infection • Immunology • Infectious Disease • Solid Organ Transplantation • Transplant Rejection • Transplantation • FABP1 • IGFBP7 • TIMP2